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Abstract
Nanofibers have attracted increasing attention in drug delivery and other biomedical applications due to their
some special properties. The present study aims to prepare a fiber-based nanosolid dispersion system to enhance
the bioavailability of curcumin (CUR). CUR-loaded polyvinyl pyrrolidone (CUR@PVP) nanofibers were successfully
prepared via electrospinning. Scanning electron microscopy (SEM) was employed to observe the morphology of
the nanofibers, and the SEM image showed that the drug-loaded nanofibers were smooth, and no CUR clusters
were found on the surface of the nanofibers. The results of X-ray diffraction (XRD) demonstrated that the CUR was
evenly distributed in the nanofibers in an amorphous state. Fourier transform infrared (FTIR) spectroscopy analysis
indicated that intermolecular hydrogen bonding occurred between the CUR and the polymer matrix. In vitro
dissolution profiles showed that CUR@PVP nanofiber could be quickly dissolved in phosphate-buffered saline (PBS)
solution, while negligible dissolution was observed in pure CUR sample. Importantly, in vitro cell viability assays and
in vivo animal tests revealed that the nanosolid dispersion system dramatically enhanced the bioavailability and
showed effective anticancer effect of the CUR.
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Background
Curcumin (CUR), a natural occurring phenolic sub-
stance, which was widely used as a coloring agent
and traditional medicine in certain Asian countries
for many centuries [1]. CUR can be extracted from
many different plant species, and it has been found
that CUR exhibits various pharmacological activities,
including anti-inflammatory, antioxidant, antiviral,
antiarthritic, and anticancer activities, as reported re-
cently [2–8]. The detailed mechanism of these func-
tions is complex and mainly involves cell apoptosis
by modulation of complex molecular targets [9–13].
Further, toxicity tests in humans and animals proved
that CUR caused no obvious physiological abnor-
mity, even at very high doses [14]. However, CUR is
insoluble at an acidic pH and unstable at an alkaline
pH in water, resulting in poor gastrointestinal ab-
sorption [15, 16]. After oral administration, only a
minute amount of CUR appears in the blood circula-
tion; the majority of the administered CUR was ex-
creted in its simplest form in the feces. As a result,
despite its pharmacological efficacy and safety, this
low bioavailability has restricted the clinical develop-
ment of CUR [17].
Several techniques, such as nanoparticle, micelle,
and liposome formation, have been reported to en-
hance the bioavailability of CUR [18–21]. Although
these novel methods are very promising, certain limi-
tations to their applications in medical practice still
exist. The preparation technology and conditions of
CUR nanoparticles are relatively complex, so these
particles are not suitable for extensive production.
Moreover, the biocompatibility of certain polymers
used in some micelles and liposomes is still unknown,
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and thus, these formulations could not be applied in
clinical treatment. In addition, the structural stability
and loading efficiency of these formulations are also
considered as restrictions to their practical use.
Solid dispersion is one of the pharmaceutical methods
that can improve drug dissolution and enhance the
bioavailability of poorly soluble drugs [22, 23]. This
method involves the dispersion of active agents in a
water-soluble polymer matrix prepared by co-melting
or solvent evaporation. Typically, the release rate of
the compound depends on the properties of the matrix
polymer. When the solid dispersion is immersed in
aqueous media, the polymer dissolves, and the medi-
cine is released as colloidal particles in suspension,
contributing to the improvement of dissolution and
bioavailability [24–26]. To date, many water-soluble
polymers, such as polyvinyl pyrrolidone (PVP), polyvi-
nyl alcohol (PVA), and polyethylene glycol (PEG),
have been used as dispersion matrix polymers for
solubilization of poorly soluble drugs and thus for
evaluation of the drugs’ bioavailability.
Electrospinning has been recognized as a simple and
effective method to produce extremely fine polymer fi-
bers with diameters ranging from micrometers to nano-
meters. Due to their large specific surface area, these
fibers have wide biomedical applications [27, 28]. Elec-
trospun fibers were first used as drug delivery systems
(DDSs) in 2002 [29] and have been developed as an ef-
fective way of providing fast-dissolving DDSs [30–32].
Compared with the original drug form, drug-loaded fi-
bers exhibit an extremely fast release rate. Yu et al. have
developed electrospun PVP fibers as the basis of a fast-
dissolving DDS capable of forming solid dispersions and
improved the dissolution profiles of poorly water-soluble
drugs for possible oral delivery applications [30]. To the
best of our knowledge, few reports have described elec-
trospun CUR-loaded nanofibers for in vivo investigation
of cancer treatment.
Hence, we aimed to employ electrospun PVP nanofibers
to enhance the dissolution and bioavailability of CUR,
thus improving its pharmacological effects, as shown in
Fig. 1. The morphology, physical, and chemical structure,
Fig. 1 Schemtic illustration for (a) curicumin which are water insoluble and (b) the construction of CUR@PVP nanofiber and investigation of
pharmacological effects in vitro and in vivo
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in vitro drug release profiles, and anticancer effect in vitro
and in vivo are investigated.
Methods
Materials
PVP K90 (average molecular weight = 1,300,000) was
kindly donated by Chineway International Corporation
(Shanghai, China). CUR powder (98 %) was purchased
from Aladdin Industrial Inc. (Shanghai, China). The
water used was ultra-pure, produced by a Milli-Q sys-
tem (Millipore, Billerica, MA, USA). Other chemicals
and reagents employed in the experiments were of ana-
lytical grade and were used as received from Sinopharm
Chemical Reagent Co., Ltd. (Shanghai, China), without
further purification.
Preparation of CUR-Loaded Nanofiber Mats by
Electrospinning
Spinning solutions were prepared by dissolving 1 g
PVP in a 10-ml acetic ether with stirring for 4 h at
40 °C and then adding 10, 15, or 20 wt% CUR (rela-
tive to PVP) to the solution with stirring for 2 h at
37 °C. In the electrospinning process, a high-voltage
power supply (BGG6-358, BMEI Co., Ltd. China)
was used to provide voltage (15 kV). To avoid air
bubbles, the spinning solutions were carefully loaded
into a 5-ml syringe, to which a stainless-steel capil-
lary metal-hub needle with an inside diameter of
0.5 mm was attached. The positive electrode of the
high-voltage power supply was connected to the nee-
dle tip. The earthed electrode was connected to a
metal collector wrapped with aluminum foil. Electro-
spinning was carried out under ambient conditions,
and fibers were collected 15 cm from the syringe tip.
The feed rate of the solutions was controlled at
2 ml/h using a single syringe pump (789100C, Cole-
Parmer Instruments, USA). As-prepared samples
were dried under vacuum to remove residual organic
solvents before further use.
Characterization
The morphology of the electrospun nanofibers was
observed using scanning electron microscopy (SEM)
(JEOL JSM-5600LV, Japan) at an acceleration voltage
of 8–10 kV. Prior to imaging by SEM, samples were
sputter coated with gold for 50 s to increase their con-
ductivity. The nanofiber diameter was obtained from
at least 50 measurements on a typical SEM image
using Image J 1.40 G software (NIH, USA). Further
examination of nanofiber fluorescence was performed
on Olympus BX51 fluorescence microscope. The
nanofiber samples were prepared by collecting nanofi-
bers on a glass slide under electrospinning nozzle for
1 min and then captured using Olympus DP72 camera
equipped with Olympus CellSens software. A Nicolet-
Nexus 670 Fourier transform infrared (FTIR) spec-
trometer (Thermo Fisher Scientific, Waltham, MA)
was used to obtain the FTIR spectra of the electrospun
nanofibers over a range of 500–4000 cm−1 at a scan-
ning resolution of 2 cm−1. X-ray diffraction (XRD)
spectroscopy was carried out on a Rigaku D/max 2550
PC (Rigaku Inc., Japan) with Cu Kα radiation. The op-
erating voltage and current were kept at 40 kV and
300 mA, respectively. The electrospun nanofiber sam-
ples were examined between 0 and 60° (2θ) at a scan-
ning rate of 1° (2θ) per minute.
In Vitro Drug Dissolution Tests
The in vitro dissolution of the CUR-loaded nanofibers
and free CUR was examined in 50-ml phosphate-
buffered saline (PBS; pH 7.4) at 37 °C for 48 h. In a
typical process, 100 mg CUR-loaded polyvinyl pyrroli-
done (CUR@PVP) nanofiber mats (containing 10 mg
of CUR) and 10 mg of pure CUR powder were added
into the released solvent, respectively. Subsequently,
aliquots (200 μl) were withdrawn at predetermined
time intervals (0.5, 1, 2, 4, 8, 12, 24, and 48 h) and
then replaced with an equal volume of PBS to main-
tain a constant volume. At last, the samples were
transformed into HPLC vials after filtering by a mem-
brane disc filter (ME@PES Syringe Filter, Membrane
Solutions, USA).
The analysis of CUR was based on previous studies
[33], with modification. Briefly, the samples were per-
formed using an Agilent 1200 high-performance liquid
chromatography (HPLC) system combined with the
AB SCIEX API-4000 quadrupole mass spectrometer as
a detector. An Agilent Eclipse XDB-C18 (4.6 × 150 mm,
3.5 μm) was selected as the separation column and
maintained at 45 °C. The mobile phase, with a total
rate of 300 μl/min in gradient mode, was composed
of water and methanol, each containing 0.2 % formic
acid. The key parameters for CUR analysis, the
declustering potential (DP), collision energy (CE), and
collision cell exit potential (CXP) were fixed at −70, −50,
and −12 V, respectively.
Cell Culture
A murine melanoma cells line, denoted B16, was pur-
chased from the Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China). The B16 cells
were maintained in RPMI 1640 medium containing 10 %
FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin in a
humid atmosphere of 5 % CO2 and 95 % air at 37 °C. The
medium was changed every day, and the cells were pas-
saged by trypsinization before confluence.
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In Vitro Cytotoxicity Assessment
The cytotoxicity of the samples was evaluated using
a Cell Counting Kit-8 (CCK-8; Beyotime Institute of
Biotechnology, China) assay according to the manu-
facturer’s instructions. B16 cells were seeded at a
density of 5000 cells per well on 96-well plates and
allowed to settle overnight. Free CUR, free CUR dis-
solved with the aid of DMSO and CUR@PVP nanofi-
ber, with various concentrations of CUR in medium
(corresponding to 5, 10, 20, or 40 μg/ml CUR), were
subsequently prepared and added to the 96-well
plates. Cells were treated with PVP nanofibrous mats
as controls. After incubation for 24 or 72 h, the cells
were washed once with PBS, and 10 μl CCK-8 solu-
tion in a 90-μl serum-free RPMI 1640 medium was
added to each well and then incubated at 37 °C for
4 h. The cell viability was determined by measuring
the optical absorbance at 450 nm using a microplate
reader (Multiskan MK3, Thermo Labsystems).
Animal and Treatment
Naïve male C57BL/6 mice (approximately 5–7 weeks
old) without specific pathogens were ordered from
Shanghai SIPPR-BK Laboratory Animal Co., Ltd.
Health assessment, including evaluation of the ori-
fices, coat, and extremities, was performed on each
animal every day before an experiment to avoid test-
ing error. The room temperature was maintained at
23–26 °C with HEPA-filtered air at a rate of 15–25
air changes per hour. In addition, the relative hu-
midity was controlled at 40–70 %, and a fluorescent
light was used as illumination for a 12-h light and
12-h dark cycle. Finally, all animal experiments were
humanely conducted in compliance with the Institu-
tional Animal Care and Use Committee (IACUC)
guidelines.
In Vivo Pharmacokinetics (PK) Test
For in vivo PK testing, a total of 48 male C57BL/6
mice were randomly divided into two groups (n = 24
per group), and 3 mice were assigned to each phar-
macokinetic time point. All tested mice needed to be
fasted overnight (12 h) during the experiment to
avoid the absorption of CUR being influenced by
food. Free CUR or CUR@PVP nanofibrous mats
were orally administered to each group at a dose of
25 mg/kg. The mice were anesthetized with 5 % iso-
flurane at designated time points (pre-dose and 0.25,
0.5, 1, 2, 4, 8, and 12 h) via retro-orbital injection,
and blood samples (approximately 300 μl) were col-
lected from each mouse. The collected blood, treated
with the anticoagulant K2-EDTA, was centrifuged at
5000 rpm for 10 min at 4 °C to separate the plasma.
The plasma samples were protected from light and
stored at −80 °C before analysis. Prior to the ana-
lysis, plasma samples were mixed with the equal
volume methanol and then centrifuged at 12,000 rpm/min
in 4 °C for 10 min. The supernatant was carefully
removed for LC-MS/MS analysis. The plasma drug
concentration was finally calculated using external
standard method with the accuracy at a 90–110 %
range.
In Vivo Anticancer Treatment
The in vivo anticancer test chiefly inspected the effect
of the agents on the growth of mouse melanoma B16
cells administered to C57BL/6 mice as subcutaneous
allografts. The mice were divided into three groups
(each group = 20) and then treated with PVP, pure
CUR, and CUR@PVP nanofibrous mats, respectively.
The dosage of pure CUR and CUR@PVP nanofibrous
mat groups were fixed at 50 mg curcumin per kilo-
gram of mice body weight, and the PVP nanofiber
group used as a control treated by the same amount of
PVP K90.
For cancer model preparation, all mice were shaved
on their right armpits and then subcutaneously sub-
jected with a single injection of 1 × 106 B16 cells in
PBS. After cell injection, all groups were orally ad-
ministered every day. The size of the resultant tumors
was assessed blindly every day, and the tumor area
(mm2) was assessed by measuring the maximum
diameter with a caliper. At the end of the experiment,
all mice were euthanatized by over-dosing pentobar-
bital sodium injection. The tumor of each mouse was
carefully dissected from the normal subcutaneous tis-
sue and then immersed in 4 % formalin PBS solution.
After the 48-h fixation, the tumor was dehydrated
with gradient alcohol-water solution and then embed-
ded in paraffin, sectioned at 8 mm, and performed
masson-trichrome (Masson) and hematoxylin & eosin
(H&E) staining. At last, the stained tissue lesion was
examined under a digital microscope.
Statistical Analysis
Statistical analysis of the results was performed using
one-way analysis of variance (ANOVA), followed by
Student’s t test. The criteria for statistical significance
were *P < 0.05 and **P < 0.01.
Results and Discussion
Morphological Analysis
Representative SEM images of PVP and CUR@PVP
nanofiber are shown in Fig. 2. It can be observed
that bead-free, smooth, and uniform nanofibers were
obtained. The diameter of the electrospun PVP
nanofiber was 888 ± 134 nm (Fig. 2a). However, the
diameter of the CUR@PVP nanofiber was sharply
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decreased (485 ± 123 nm) (Fig. 2b), suggesting that
the incorporation of polar CUR might increase the
electrospinning solution’s conductivity, thereby en-
hancing the electrical drawing effects on the jet fluid
and decreasing the fiber fineness [34]. Fluorescence
images of CUR@PVP nanofibers taken in the dark
field were represented in Fig. 3a−c. It was noted that
the red fluorescence of the nanofiber was observed.
Because pure PVP nanofibers are not fluorescent
whereas curcumin could be excited at 447 nm [35],
it was reasonable to consider fibers with red fluores-
cence due to the uniform distribution of curcumin
Fig. 2 The SEM images and fiber diameter distribution histograms of (a, b) PVP and (c, d) CUR@PVP nanofiber
Fig. 3 Fluorescent images of CUR@PVP nanofiber prepared with (a) 10 wt%, (b) 15 wt%, and (c) 20 wt% CUR. d FTIR spectra and (e) XRD data of
CUR, CUR@PVP nanofiber, and PVP nanofiber
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within PVP nanofiber matrix. We observed that
when the adding amount of CUR was more than
10 wt%, CUR crystals were formed on the nanofi-
bers. Hence, both SEM and fluorescence photos re-
vealed that after blend electrospinning of PVP and
CUR, 10 wt% of CUR was evenly incorporated
within the PVP, and no crystals were separated out,
indicating the electrospinning process parameters
were suitable, and the method was feasible for prep-
aration of CUR nanosolid dispersion system. Thus,
CUR@PVP nanofiber prepared with 10 wt% of CUR
was used in the following experiments.
FTIR Analysis
FTIR spectral data are shown in Fig. 3d. CUR showed
five characteristic peaks. The peak at 1627 cm−1 was
due to the stretching of the C=O group, which was
shifted to a lower wavenumber than usual C=O
stretching (1680–1750 cm−1) due to conjugation
present around the carbonyl group. Peaks at 1602
and 1508 cm−1 appeared due to aromatic C=C
stretching. Phenolic C–O stretching appeared at
1427 cm−1, and an enolic C–O stretching peak ap-
peared at 1281 cm−1. The spectrum of PVP showed a
characteristic peak at 1660 cm−1 (C=O stretch). In
addition to the significant peaks of PVP, the charac-
teristic peaks of CUR can be observed for the
CUR@PVP nanofiber, including aromatic C=C
stretching at 1602 and 1508 cm−1, and significant
broadening of peaks in the region of 3600–3400 cm−1
were noted, which may be attributed to intermolecu-
lar hydrogen bonding [36]. Collectively, these data in-
dicate that either CUR or PVP retained its individual
properties, and there is no chemical change due to
the electrospinning approach. These findings are
consistent with numerous studies which have shown that
active ingredients undergo the electrospinning process
without any change in their structural integrity or any
loss of their effectiveness as active pharmaceutical
agents [34, 37–40].
XRD Analysis
As can be observed in Fig. 3e, the powder XRD pat-
terns of CUR showed characteristic high-intensity dif-
fraction peaks at 2θ values of 8.6, 11.95, 14.28, 17.08,
18, 20.87, 23.21, 24.31, and 25.41, indicating a crystal-
line nature. However, no characteristic diffraction peaks
corresponding to CUR were observed for CUR@PVP
nanofiber, suggesting of a low-order or amorphous state
for the CUR.
In Vitro Drug Dissolution Tests
Figure 4 shows the dissolution profiles of pure CUR
and CUR@PVP nanofiber. As shown in Fig. 4, pure
CUR showed negligible dissolution, even after 50 h.
In contrast, CUR@PVP nanofiber showed a drastic
increase in their dissolution rate, and the medium in
the dissolution flask was yellow, indicating the pres-
ence of a stable neutral form due to the formation
of a high-energy amorphous phase, as supported by
the XRD data. In previous research [40], fiber mats
comprising ibuprofen and PVP K30 were able to dis-
solve within 10 s in in vitro dissolution tests. In the
present study, for CUR@PVP nanofiber, a dissolution
rate above 90 % was observed within 15 min. However,
the rate decreased to 89 % at 48 h. The decrease in
dissolved CUR over time was predominantly caused
by precipitation of the drug, which existed in a super-
saturated state in buffer. The precipitated drug was
visually observed after completion of the dissolution
tests. These results indicate that electrospun PVP
nanofibers have the potential to be used to create
fast-dissolving drug release systems for poorly water-
soluble drugs and their derivatives.
In Vitro Cytotoxicity Assessment
Before conducting the in vivo experiments, the
in vitro cytotoxicity of free CUR, CUR dissolved in
DMSO, and CUR@PVP nanofibers was performed by
testing the viability of B16 cells at CUR concentra-
tions of 5, 10, 20, and 40 μg/ml (the relative concen-
trations of PVP were 50, 100, 200, and 400 μg/ml,
respectively) after incubation for 24 or 72 h. The cell
viability after exposure to unloaded PVP nanofibers
was also investigated to eliminate the possible influ-
ence of PVP on cytotoxicity. As shown in Fig. 5,
blank PVP nanofibers have nearly no obvious cyto-
toxicity to B16 cells at the measured concentrations
Fig. 4 In vitro dissolution profiles of pure CUR and CUR@PVP nanofiber
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within the studied time periods. We observed a drug
concentration-dependent cytotoxicity to B16 cells for
both CUR dissolved with the aid of DMSO (CUR in
DMSO) and CUR@PVP nanofiber. As expected, both
CUR in DMSO and CUR@PVP nanofiber showed
significant decrease in cell viability at the CUR dose
over 10 μg/ml for both 24 and 72 h, and no signifi-
cant difference between them was observed. After
incubation for 72 h, the cell viability for CUR@PVP
was decreased to 24.4 and 20.9 % at the CUR con-
centrations of 20 and 40 μg/ml, respectively (Fig. 5b).
Unexpectedly, in comparison, an irregular decrease
in B16 cell viability was obtained for the pure CUR
group. This result was probably due to the fact that
a large proportion of CUR molecules were hardly
soluble, and thus, the CUR was not well distributed
throughout the cell medium. These results, which
were consistent with the release profiles of CUR
(Fig. 4), suggested that CUR@PVP nanofiber could
promote the solubility of CUR, therefore exhibiting
an evident growth-inhibiting effect on the B16 cells
compared with free CUR.
In Vivo PK Test
Bioavailability is an important parameter, referring to
the extent at which active agents are exposed to the
circulation, which determines the amount of drug
available to a target organ or site. Commonly, the
rate of bioavailability depends on factors including
the drug’s physicochemical properties (such as solubil-
ity or polarity) and formulation [41]. In the present
study, CUR in mouse plasma was detected over time
Fig. 6 Plasma concentration vs. time profile. Plasma concentration
of CUR in C57BL/6 mice. Values are mean ± SEM (n = 3)
Fig. 5 In vitro cytotoxicity of free CUR, CUR dissolved in DMSO, and CUR@PVP nanofiber was performed by testing the viability of B16 cells in
CUR concentration of 5, 10, 20, and 40 μg/ml for incubation of (a) 24 h and (b) 72 h. **Significant difference compared to free CUR (P < 0.01)
Table 1 Pharmacokinetic parameters of CUR fraction following
single dose oral administration of CUR and CUR@PVP nanofiber
in C57BL/6 mice (n = 24) at 25 mg/kg
Parameter CUR CUR@PVP nanofiber
Cmax (ng/ml) 14 ± 3 167 ± 19***
Tmax (min) 120 60
AUC0−t (ng.min/ml) 2720 ± 124 31,238 ± 563***
Values reported as mean ± SEM (n = 24). AUC area under the plasma
concentration-time curve, Cmax peak concentration, Tmax time to reach peak
concentration. ***P < 0.001
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after oral administration of either free CUR or CUR-
loaded nanofibrous mats. The PK data are summa-
rized in Fig. 6 and Table 1. The concentrations of
total curcuminoids in the plasma increased to their
highest levels (167 ng/ml) at 60 min after administra-
tion and thereafter decreased gradually. Additionally,
the peak concentration (Cmax) and the area under the
curve (AUC) of the CUR-loaded nanofibrous mats
were increased by 11-fold and 10-fold compared with
those of free CUR, contributing to the increased bio-
availability of the CUR nanosolid dispersion. This result
may be attributed to the crystalline and amorphous na-
tures of the unformulated CUR and the CUR nanosolid
dispersion, respectively, as confirmed by XRD analysis.
Previous studies using crystalline ritonavir, an anti-HIV
drug, have demonstrated solubility-limited absorption
[42], whereas the amorphous dispersion exhibited in-
creased bioavailability because of an apparent increase
in solubility.
In Vivo Anticancer Test
All animals challenged with B16 cells presented small
nodules after 4 days, indicating successful model prep-
aration. The tumor growth curve is shown in Fig. 7. It
was found that the increase in the tumor size in PVP
group was slightly quicker than that in the pure
CUR group but visibly faster than that in the
CUR@PVP group (Fig. 7a). Figure 7b revealed that
the CUR@PVP group displayed much higher effi-
ciency in inhibiting tumor growth compared with
PVP group and CUR group, which was attributed to
the result of the enhanced bioavailability of the CUR
nanosolid dispersion, as mentioned above. The hist-
ology images of the tumor from different groups
were shown in Fig. 8. H&E staining demonstrate that
the allografts in mice were generated from the
injected B16 cells. The tumor necrosis area was la-
beled as capital S, and the other tissue was recog-
nized as N (Fig. 8a). From the micrograph, the
necrosis area of CUR@PVP group is significantly lar-
ger than PVP and pure CUR groups, and pure CUR
group was slightly different with PVP group, which
was agreed with tumor growth curve. Masson stain-
ing revealed the tumor cell proliferation between the
margin of tumor and mouse hypodermis and further
illustrated tumor cell’s invasion ability (Fig. 8b). In
the Masson lesion photo, the margins of each sample
were labeled as M. It was demonstrated that tumor
invasion ability in PVP group was most powerful,
followed by pure CUR and CUR@PVP groups. From
Fig. 7 a Digital photo of tumor with treatment of different samples at day 32, (b) tumor volume vs. time profile. Values are mean ± SEM (n = 20).
**denotes significant differences (P < 0.01) against control group, ## denotes significant difference (P < 0.01) against CUR group
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the in vivo anticancer test, we found that CUR@PVP
could not only induce the cancer cell apoptosis but
also fade its invasion ability.
Conclusions
PVP nanofibers containing CUR have been successfully
prepared by electrospinning. SEM analysis showed that
no CUR clusters were found on the surface of the
nanofibers and that the surface was smooth. Further-
more, the CUR in the composite nanofibers was pre-
sented in an amorphous state, as confirmed by XRD
analysis. FTIR spectra suggested that CUR and PVP
have good compatibility due to hydrogen bonding be-
tween them. In vitro dissolution tests verified that the
drug-loaded PVP nanofibers were able to dissolve very
quickly. Finally, the CUR@PVP nanofiber showed en-
hanced bioavailability and effective anticancer effect via
CUR, which are promising properties for the develop-
ment of CUR-based anticancer therapeutics with en-
hanced bioavailability.
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